tablets Femoston of Konti pass are applied at the replacement hormonal therapy (RHT) to elimination of the symptoms caused by deficiency of estrogen at women during the menopauzny period not earlier than in 12 months from the moment of the last periods.

Structure

Active ingredients: didrogesteron; oestradiol;

didrogesteron micronized 2.5 mg and oestradiol of the gemigidrat micronized that is equivalent oestradiol of 0.5 mg;

Excipients: lactose monohydrate, gipromelloz (HPMC 2910) starch corn dioxide of silicon colloidal stearate of magnesium film cover Zhelty 1 (macrogoal 3350, polyvinyl alcohol, talc, titan dioxide (E 171), ferrous oxide yellow (E172)).

Contraindication

• known hypersensitivity to active ingredients or to any of medicine excipients;
• cancer of mammary glands diagnosed in the past, available or suspected;
• established or suspected estrogenchuvstvitelny tumors (for example endometrial cancer);
• vaginal bleedings of not clear genesis;
• not treated hyperplasia of endometrium;
• an active venous thrombembolia in the anamnesis (deep vein thrombosis, a thrombembolia of pulmonary arteries);
• existence of trombofilichesky frustration (for example deficiency of a protein With, a protein of S or antithrombin);
• acute or recently postponed thromboembolic disease of arteries (for example stenocardia, a myocardial infarction);
• an acute disease of a liver or a disease of a liver in the anamnesis at which indicators of function of a liver were not normalized;
• porphyria.

Route of administration

For intake.

Prolonged use of a combination: estrogen and progestogen accept to rummage daily without interruption. It is necessary to accept on one tablet to a tablet in day during throughout a 28-day cycle.

Femoston of Konti pass it is necessary to accept constantly, without interruption from different packings to rummage in reception of tablets.

For a start for a start and continuations of treatment of post-menopausal symptoms should apply a minimal effective dose during throughout the minimum span.

Drug is not shown to

Feature of application

for application during pregnancy.

Children

by

for application for children.

Drivers

Drug does not influence or has insignificant impact on ability to drive the car or to work with mechanisms.

Overdose

As oestradiol, and didrogesteron are substances with hypotoxicity. At overdose there can be such symptoms as nausea, vomiting, sensitivity of mammary glands, dizziness, an abdominal pain, drowsiness/fatigue and bleeding of cancellation. It is improbable that at overdose any specific or symptomatic treatment will be required. Information described above belongs also to overdose cases at children.

Side effects

Most frequent side reactions at patients to whom performed therapy by oestradiol / didrogesteronom at conduct of clinical trials were a headache, an abdominal pain, pain/sensitivity of mammary glands and a back pain.

Researches of medicinal interactions were not conducted by

.

Storage conditions

to Store out of children's reach the place - darlings.

does not demand special storage conditions.

Expiration date - 4 years.